Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.
Michael Choi, MD, discusses several key considerations for the treatment of chronic lymphocytic leukemia from his presentation at a recent OncLive® State of the Science Summit™ on hematologic malignancies.
Pooja Advani, MBBS, MD, details key advancements and the significance of pivotal trials that were presented by her colleagues at a recent OncLive® State of the Science Summit™ on breast cancer, which she chaired.
Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.